If you do not succeed at the beginning, try again – in separate regions. It is the motto in pharmaceutics began that follows, at least, after having disclosed, he continued Pfizer in Europe for a patent infringement relating to the covid-19 paxlovid treatment pill (nirmatrelvir / ritonavir).
In June 2022, began a complaint against Pfizer before an American Massachusetts district court, saying that the large pharmaceutical enterprise inflicted on a patent describing protease inhibitors invented by its scientists. Begun now followed this with another file in Europe, making the same accusation.
Since the emergency authorization in 2021, Paxlovid Antiviral has generated more than $ 26 billion in world income. This includes an amazing 18.9 billion dollars in 2022 when Cavid-19 cases were still widespread. Despite the decreasing demand for Treatments COVID-19, the pill still reported $ 1.2 billion in 2024, supported by government orders.
However, the EANTA – known for having co -developed the treatment of the virus of hepatitis C glecaprevir / pibrentasvir with abbvie – thinks that pfizer has designed Paxlovid by illegal means.
American biotechnology has declared that it “is looking for a determination of responsibility for the use and violation of the European patent N ° EP 4 051 265 (the” 265 patent) in the manufacture, use and sale of PFID-19 Antiviral, Paxlovid “of Pfizer”.
In a declaration sent by e-mail to Pharmaceutical technology, A spokesperson for Pfizer said: “We are confident in our intellectual property (IP) surrounding Paxlovid and will answer in due time.”
The trial, submitted to the UE UE (UPC) unified patent court (UPC), targets the commercial activity of Pfizer in the 18 countries of the EU. The company confirmed that the “265 patent in question is the European counterpart of the American patent 11 358 953 (the” patent 953) which is the center of the American trial.
Although it is technically underway, the US trial of Enanta has struck a major obstacle. In December 2024, a federal judge of Massachusetts ranked on the side of Pfizer, granting that the patent 953 is not valid. Begun confirmed when he appealed the decision, adding it “firmly believes in the bottom of our case”.
Pfizer reported solid results from T2 2025 this month, cutting a lukewarm income window that seized the wider pharmaceutical industry. Paxlovid sales increased by 71% while COVVI-19 Return Cournaty has jumped 95%.
However, the judicial challenge posed by Enana marks the second issue that Pfizer had to make fire this week. The large pharmaceutical company reported a phase III test failure for a sickle cell candidate purchased as part of a takeover of $ 5.4 billion in global blood therapies in 2022.
